List of Diagnostics Companies in Japan - 8

Pharmaceuticals, diagnostic reagents, medical devices

The HORIBA Group of worldwide companies provides an extensive array of instruments and systems for applications ranging from automotive R&D, process and environmental monitoring, in-vitro medical diagnostics, semiconductor manufacturing and metrology, to a broad range of scientific R&D and QC measurements. Proven quality and trustworthy performance have established widespread confidence in the HORIBA Brand.

Medmain Inc. is a company to develop and provide "PidPort", a pathological AI analysis solution, with a corporate mission of "to create a world where medical services can be accessed with technology anywhere, anytime." "PidPort" is a product that enables the presentation of highly accurate and rapid analysis results by pathology AI developed by deep learning and the online pathological diagnosis such as remote pathological diagnosis. There is a worldwide shortage of "pathologists" who make diagnoses of patients by looking at their tissues and cells to determine whether there is cancer or not and decide the treatment plan, and this has led to serious delays in pathological diagnosis and large regional disparities. With our product "PidPort", we aim to solve this problem and create a world in which patients can receive a high-quality pathological diagnosis immediately wherever they are.

Mochida Pharmaceutical - By aiming to become a comprehensive healthcare company, Mochida Pharmaceutical has made significant contributions in the field of medical care through its pharmaceuticals, healthcare products, and medical equipment businesses. Several years back, to improve the profitability, competitiveness value of all its divisions, Mochida Pharmaceutical split off the Medical Electronics and Equipment Division in 2003, the Healthcare Division in 2004 and the Pharmaceutical Manufacturing Division in 2005. Currently, the Group consists of Mochida Pharmaceutical and five consolidated subsidiaries. We at the Mochida Pharmaceutical Group remain committed as ever to contributing to peoples' health and well-being.

Oncolys BioPharma Inc. is a Tokyo-based bioventure established in Japan in March 2004. Its mission is to contribute to the advancement of medical science in the world through bringing innovation to the existing treatments for cancer and serious infectious diseases, using its virology-based new drug discovery technologies. The company operates in two business segments. Pharmaceutical Business segment is engaged in the research, development, manufacture and marketing of novel drugs. Its major pipeline Telomelysin (OBP-301), an oncolytic adenovirus immunotherapy is in clinical development targeting various types of solid tumors including melanoma , HCC and esophageal cancer. Along with Telomelysin, an anti-HIV drug OBP-601 (Censavudine) and a novel HDAC inhibitor OBP-801 are also under development in the United States. Diagnostics Business segment is engaged in the research, development, manufacture and marketing of CTC (Circulating Tumor Cell) detection adenovirus TelomeScan, as well as the provision of inspection services. Oncolys was listed on the Tokyo Stock Exchange Mothers Market in December 2014 and has a clinical laboratory center in Kobe, Japan and a subsidiary in New Jersey, USA.

REPROCELL supports nearly the entire workflow of stem cell research and pre-clinical drug development. Our unique portfolio includes access to human tissues (BioServe) and human tissue testing (Biopta), in addition to stem cell culture media, reprogramming technologies, reagents, and iPSC-derived cell types (Stemgent). With our deep knowledge of stem cell biology, bioengineered (3D) tissue models (Alvetex) cell differentiation, and pharmacology, REPROCELL is a recognized leader in cutting-edge tools and services to accelerate regenerative medicine and drug development. The newly formed REPROCELL Medical business unit is developing a suite of reagents and services to meet the growing need for clinical-grade products and services that are appropriate for regenerative medicine. In addition, our labs offer diagnostic services for a variety of tests related to tissue compatibility and other biomarkers. And finally, REPROCELL also offers a GMP iPSC master cell bank manufacturing service. *** REPROCELL went public on the Japan JASDAQ in June 2013. Stemgent, BioServe and Reinnervate became parts of REPROCELL in 2014. Biopta was then acquired in 2015.

The Separation and Purification group of Tosoh Bioscience, a division of Tosoh Corporation, is a major global supplier of chromatographic solutions predominately serving the pharmaceutical, biotechnology, and chemical industries. Since 1987, our product portfolio has expanded and evolved to anticipate industry demands and exceed our customers' needs. Our comprehensive line of analytical HPLC columns, bulk process media resins, and dedicated GPC systems for polymer analysis, coupled with our expertise, make the solution to your separation and purification process clear. Tosoh Corporation, headquartered in Tokyo, Japan, is the parent of a global chemical and specialty materials group. All instruments, columns, and media sold by the Tosoh Bioscience Separations & Purification group are manufactured at Tosoh's Nanyo Complex in Yamaguchi, Japan. Tosoh Bioscience Separations & Purification Group Facilities: • Tosoh Corporation, Bioscience Division – Japan • Tosoh Bioscience LLC – North and South America • Tosoh Bioscience GmbH – Europe, Middle East, Africa • Tosoh Bioscience Shanghai Co., Ltd. – China • Tosoh Asia, Pte. Ltd. – Southeast Asia • Tosoh India Pvt. Ltd. – India